Ronica H Nanda1,2, Yuan Liu2,3,4, Theresa W Gillespie2,3, John L Mikell1,2, Suresh S Ramalingam2,5, Felix G Fernandez2,6, Walter J Curran1,2, Joseph Lipscomb2,4, Kristin A Higgins1,2. 1. Department of Radiation Oncology, Emory University, Atlanta, Georgia. 2. Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Department of Biostatistics and Bioinformatics Shared Resource, Emory University, Atlanta, Georgia. 4. Rollins School of Public Health, Emory University, Atlanta, Georgia. 5. Department of Hematology and Oncology, Emory University, Atlanta, Georgia. 6. Department of Surgery, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Stereotactic body radiation therapy (SBRT) has demonstrated high rates of local control with low morbidity and has now emerged as the standard of care for medically inoperable, early stage non-small cell lung cancer (NSCLC). However, the impact of lung SBRT on survival in the elderly population is less clear given competing comorbid conditions. An analysis of the National Cancer Data Base (NCDB) was undertaken to determine whether definitive SBRT improves survival relative to observation alone patients ages 70 years and older. METHODS: The NCDB, a retrospective national database that captures approximately 70% of all patients treated for cancer, was queried for patients aged 70 years or older with early stage (T1-T3N0M0) NSCLC from 2003 to 2006. Overall survival was compared between patients who received stereotactic body radiotherapy alone and those who received no treatment. An extended Cox proportional hazards model was applied to estimate the treatment effect of SBRT. RESULTS: In total, 3147 patients met the selection criteria for this analysis. SBRT was delivered to 258 patients (8.2%), and 2889 patients (91.8%) received no treatment. There was no significant difference in the distribution of Charlson/Deyo comorbidity index scores between the 2 groups (P = .076). Multivariable analysis revealed improved overall survival with SBRT compared with observation for the entire cohort (hazard ratio, 0.64; P < .001). CONCLUSIONS: SBRT is associated with improved survival in elderly patients with early stage NSCLC who have concurrent comorbid conditions compared with observation alone. The current data support the use of SBRT for the treatment of elderly patients with early stage NSCLC who have limiting comorbid conditions.
BACKGROUND: Stereotactic body radiation therapy (SBRT) has demonstrated high rates of local control with low morbidity and has now emerged as the standard of care for medically inoperable, early stage non-small cell lung cancer (NSCLC). However, the impact of lung SBRT on survival in the elderly population is less clear given competing comorbid conditions. An analysis of the National Cancer Data Base (NCDB) was undertaken to determine whether definitive SBRT improves survival relative to observation alone patients ages 70 years and older. METHODS: The NCDB, a retrospective national database that captures approximately 70% of all patients treated for cancer, was queried for patients aged 70 years or older with early stage (T1-T3N0M0) NSCLC from 2003 to 2006. Overall survival was compared between patients who received stereotactic body radiotherapy alone and those who received no treatment. An extended Cox proportional hazards model was applied to estimate the treatment effect of SBRT. RESULTS: In total, 3147 patients met the selection criteria for this analysis. SBRT was delivered to 258 patients (8.2%), and 2889 patients (91.8%) received no treatment. There was no significant difference in the distribution of Charlson/Deyo comorbidity index scores between the 2 groups (P = .076). Multivariable analysis revealed improved overall survival with SBRT compared with observation for the entire cohort (hazard ratio, 0.64; P < .001). CONCLUSIONS: SBRT is associated with improved survival in elderly patients with early stage NSCLC who have concurrent comorbid conditions compared with observation alone. The current data support the use of SBRT for the treatment of elderly patients with early stage NSCLC who have limiting comorbid conditions.
Authors: Penny Fang; Weiguo He; Daniel R Gomez; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano; Reshma Jagsi; Grace L Smith Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-01 Impact factor: 7.038
Authors: Elizabeth A David; Megan E Daly; Chin-Shang Li; Chi-Lu Chiu; David T Cooke; Lisa M Brown; Joy Melnikow; Karen Kelly; Robert J Canter Journal: J Thorac Oncol Date: 2017-01-18 Impact factor: 15.609
Authors: Richard J Cassidy; Pretesh R Patel; Xinyan Zhang; Robert H Press; Jeffrey M Switchenko; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Walter J Curran; Kristin A Higgins Journal: Clin Lung Cancer Date: 2017-03-16 Impact factor: 4.785